Hims & Hers Health Inc. ($HIMS) Stock Forecast: Down 8.1% Today

What is Hims & Hers Health Inc.?

Hims & Hers Health (HIMS) is a technology-driven healthcare company that offers telehealth services and digital health products. The company has been making strategic collaborations and expanding its product offerings in the healthcare space.

Why is Hims & Hers Health Inc. going down?

HIMS stock is down 8.1% on Apr 30, 2025 18:36

• The collaboration with Novo Nordisk to sell the weight loss drug Wegovy on its platform is a positive development for HIMS, indicating the company's focus on expanding its product portfolio and revenue streams.
• Despite the positive news about revenue generation and earnings growth expectations, the market might have reacted bearishly due to potential concerns about competition in the telehealth sector.
• Investors may be cautious about the competitive landscape and the long-term sustainability of HIMS's growth, leading to a bearish movement in the stock price despite the recent positive developments.

HIMS Price Chart

HIMS Technical Analysis

HIMS News

Hims & Hers vs. Teladoc: Which Telehealth Stock Is the Better Buy Now?

Both HIMS and TDOC are technology-intensive healthcare companies that leverage their strengths in the digital health space to enhance their platforms. Which one is a better investment? Let's see.

https://www.zacks.com/stock/news/2459343/hims-hers-vs-teladoc-which-telehealth-stock-is-the-better-buy-now

Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform - Hims & Hers Health ( NYSE:HIMS ) , Novo Nordisk ( NYSE:NVO )

Novo Nordisk's Wegovy now available via Hims & Hers at $599/month, covering all dose strengths with 24/7 care and nutrition support. Hims & Hers' GLP-1 offering, including Wegovy and Zepbound, generated over $225 million in revenue in 2024.

https://www.benzinga.com/25/04/45074872/hims-hers-stock-surges-as-it-collaborates-with-novo-nordisk-to-sell-weight-loss-drug-wegovy-on-its-platform

Hims & Hers Health, Inc. ( HIMS ) Earnings Expected to Grow: Should You Buy?

Hims & Hers Health (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

https://www.zacks.com/stock/news/2456885/hims-hers-health-inc-hims-earnings-expected-to-grow-should-you-buy

Trending Today

S&P 500 Index ($SPX) Index Forecast: Up 0.6% Today

NASDAQ-100 ($NDX) Index Forecast: Up 1.0% Today

Worldcoin ($WLD) Crypto Forecast: Up 5.7% Today

Chegg Inc. ($CHGG) Stock Forecast: Up 6.6% Today

PPG Industries Inc. ($PPG) Stock Forecast: Up 5.0% Today

Spotify Technology S.A. ($SPOT) Stock Forecast: Up 5.8% Today

Algorand ($ALGO) Crypto Forecast: Down 5.9% Today

Garmin Ltd. ($GRMN) Stock Forecast: Down 9.9% Today

Bonk ($BONK) Crypto Forecast: Down 7.5% Today

Apache Corporation ($APA) Stock Forecast: Down 5.0% Today

Hims & Hers Health Inc. Price History

21.03.2025 - HIMS Stock was down 5.1%

• Despite HIMS estimating a significant increase in sales and profits, the stock experienced a bearish movement, possibly due to macro challenges affecting its performance.
• The stock had been performing well in the past few months, gaining 5.8%, but today's bearish movement could be a result of these macro challenges overshadowing its growth prospects.
• The positive change of +1.04% in the preceding trading day did not hold, indicating a shift in market sentiment possibly triggered by concerns over the company's ability to navigate the current challenges.
• Investors might be cautious about the company's ability to sustain its growth trajectory amidst the macro challenges, leading to a sell-off and the bearish movement observed today.

28.02.2025 - HIMS Stock was down 7.6%

• The stock of HIMS experienced a strong bearish movement recently.
• Smart money investors have taken a notably bearish stance on HIMS options, as a significant percentage have opened trades with bearish sentiments.
• The stock has been down 7.1% since the last earnings report, prompting concerns about its ability to rebound.
• The overall options activity for HIMS is leaning towards a bearish outlook, potentially contributing to the downward trend in the stock price.

13.02.2025 - HIMS Stock was down 5.5%

• Despite HIMS enhancing its offerings and expanding its product line in the health and wellness sector, macro challenges seem to be impacting its performance negatively.
• An increase in trades by major investors in HIMS might indicate short-term optimism. However, the overall market sentiment has overshadowed this positive sentiment, leading to a strong bearish movement in the stock today.
• Investors might be cautious due to macro challenges, causing them to sell off their positions in HIMS, contributing to the bearish movement observed today.

16.03.2025 - HIMS Stock was down 5.2%

• The bearish movement in HIMS stock today could be due to the macro challenges impacting its performance.
• Despite efforts to enhance offerings and expand products, these challenges seem to have outweighed the positive developments.
• Investors might be cautious about the company's ability to navigate through these macro challenges successfully, leading to the bearish movement in the stock today.

12.02.2025 - HIMS Stock was down 5.1%

• Despite bullish sentiment from whales and financial giants in the options market, HIMS stock experienced a bearish trend.
• Novo Nordisk's decision to lower the costs of Wegovy, a competitor in the health sector, may have impacted investor confidence in HIMS.
• The discounted price offered by Novo Nordisk could potentially attract customers away from HIMS, leading to a decrease in the stock price.
• The bearish movement in HIMS stock could be a result of increased competition and pricing pressures in the telehealth and wellness industry.

06.02.2025 - HIMS Stock was down 11.0%

• Today's downward movement in HIMS stock may be due to profit-taking by investors following a prior period of bullish sentiment.
• Despite strong Q4 revenue and subscriber growth, the market's reaction could have been influenced by the company meeting, rather than surpassing, EPS expectations.
• Financial giants' optimistic positions in HIMS options likely initially boosted the stock, but subsequent profit-taking led to a sell-off.
• Investor focus shifting towards Novo Nordisk's reduced Wegovy costs and stock price rise may have negatively impacted HIMS performance.

26.02.2025 - HIMS Stock was down 5.6%

• The stock price of HIMS showed a strong bearish movement.
• Earnings were reported by the company 30 days ago, leading to investor uncertainty about a potential rebound.
• Options activity revealed a notable number of investors taking a bearish stance, suggesting a lack of confidence in the stock's short-term performance.
• The recent earnings report and bearish options activity likely played a role in the downward pressure on HIMS stock today.

28.03.2025 - HIMS Stock was down 6.3%

• The bearish movement in HIMS stock today could be due to investors' disappointment with the company's earnings, despite expectations of growth.
• It is possible that the actual earnings did not meet the optimistic forecasts, leading to a sell-off of the stock.
• Investors might have reacted negatively to any potential guidance or outlook provided by the company in the earnings, causing a decline in the stock price.
• The market sentiment towards HIMS could have shifted due to factors beyond just earnings, such as macroeconomic conditions or industry-specific impacts on the stock.

29.03.2025 - HIMS Stock was up 28.9%

• HIMS stock showed strong bullish movement today.
• The collaboration with Novo Nordisk to offer the weight loss drug Wegovy on its platform seems to have boosted investor confidence in Hims & Hers Health.
• Expected revenue from the GLP-1 product line, including Wegovy, and the anticipation of robust earnings growth are believed to have influenced the bullish trend in HIMS stock.
• Investors are hopeful about strategic partnerships and revenue prospects, leading to increased buying interest in HIMS shares.

25.02.2025 - HIMS Stock was up 5.7%

• Despite recent bearish options activity, Hims & Hers Health witnessed a strong bullish movement in the stock market today.
• The bullish momentum could be linked to positive earnings or key company developments fostering investor confidence.
• The bearish options activity may not have directly influenced today's stock performance, with market sentiment and other factors likely driving the upward trend.
• Positive reactions from investors to strategic partnerships, product innovations, or expansion plans might have spurred buying interest, pushing the stock price higher.

02.03.2025 - HIMS Stock was down 7.4%

• Hims & Hers Health announced an expansion of its personalized weight loss care services, which could have initially sparked investor interest and led to a positive market sentiment.
• However, the bearish movement could be attributed to the noticeable bearish stance taken by whales in HIMS options trading, indicating a lack of confidence or potential downside risk perceived by large investors.
• The uncertainty about the market's next move could have also contributed to a sell-off in the stock as investors may have chosen to take profits or cut losses amidst the mixed market sentiment.

30.03.2025 - HIMS Stock was down 8.1%

• The collaboration with Novo Nordisk to sell the weight loss drug Wegovy on its platform is a positive development for HIMS, indicating the company's focus on expanding its product portfolio and revenue streams.
• Despite the positive news about revenue generation and earnings growth expectations, the market might have reacted bearishly due to potential concerns about competition in the telehealth sector.
• Investors may be cautious about the competitive landscape and the long-term sustainability of HIMS's growth, leading to a bearish movement in the stock price despite the recent positive developments.